Objectives: To evaluate patient-perceived impact of sarilumab on RA using the RAID scale vs either placebo + conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or adalimumab. Methods: TARGET assessed sarilumab 150mg and 200mg added to csDMARDs vs placebo in patients with RA intolerant of or not responding to anti-TNF therapy. MONARCH assessed sarilumab 200mg monotherapy vs adalimumab 40mg monotherapy in patients with RA either intolerant of, inadequate responders to, or considered inappropriate candidates for continued treatment with methotrexate. Treatments were administered subcutaneously every 2 weeks. RAID has 7 single-item domains, each rated by patients on an 11-point numeric rating scale from 0 (absence) to 10 (extreme). A total score from 0 to 10 (with lower scores indicative of less impact of disease) is calculated by weighting responses for each item based on patient assessment of the relative importance of the item. RAID was assessed at baseline (BL), Weeks 12 and 24. Least square mean (LSM) changes from BL in total score (Weeks 12 and 24) and domains (Week 24 only) were analysed with a mixed model for repeated measures, including treatment, region, visit, and treatment-by-visit interaction (and prior csDMARD therapy in TARGET) as fixed effects and BL as a covariate. RAID was tested outside of trial hierarchy and statistical significance is not claimed; nominal p-values are provided. Post-hoc categorical change analyses were conducted to identify "responders" in the total score (improvements ≥ minimum clinically important difference from BL to Week 24 [absolute change of 3 or relative change of 50% in total score]). Patients discontinuing therapy/requiring rescue medication prior to endpoint were classified as non-responders. Results: Sarilumab was superior (nominal p<0.05) to placebo (TARGET) and adalimumab (MONARCH) at Weeks 12 and 24 for RAID total score (Table) . There was a greater proportion of responders in both sarilumab dose groups vs placebo at both time points (TARGET) and in sarilumab 200mg vs adalimumab at Week 24 (MONARCH). The effect of sarilumab was consistent across all 7 individual RAID domains (nominal p<0.05) at Week 24, except for sleep difficulties vs placebo in TARGET. Effects of placebo were highest on pain and effects of sarilumab were lowest on emotional well-being (TARGET) and coping (MONARCH).
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Scientific Abstracts a human monoclonal antibody directed against the IL-6 receptor-α (Table) . There was a greater proportion of responders in both sarilumab dose groups vs placebo at both time points (TARGET) and in sarilumab 200mg vs adalimumab at Week 24 (MONARCH). The effect of sarilumab was consistent across all 7 individual RAID domains (nominal p<0.05) at Week 24, except for sleep difficulties vs placebo in TARGET. Effects of placebo were highest on pain and effects of sarilumab were lowest on emotional well-being (TARGET) and coping (MONARCH).
Conclusions: Assessed using RAID, sarilumab either with csDMARDs or as monotherapy reduced the impact of RA on patients' lives to a greater extent than placebo+csDMARDs or adalimumab monotherapy, with benefits shown on total RAID and all 7 individual domain scores. Results: Levels of IL-6 (2.4 (1,1-6,4) vs 0.7 (0,62-1,0), p=0,0002), 9) vs. 64 (52,4-107,5), p=0,03), 8 ) vs 14 (9,2-15,2), p=0,005) were significantly higher in patients with RA compared to control. ABA significant reduced disease activity already after 12 weeks of therapy (p<0,05). After 24 weeks of ABA therapy good and moderate response by EULAR criteria was achieved in 86%, low disease activity by DAS28 in 52%. By the 6-th month ABA significant decreased levels of IL-6 (1,29 (0,9-2,2, p=0,0006), IP-10 (14 (7,5-28), p=0.007) as well as MMP3: before 30.1 (13-82), after 24 weeks 10 (7.4-55), p=0.0003 and RF: before 218 (9.6-187), after 24 weeks 159 (9.7-155), p=0.02. Lowering of the IL-6 (r=0,5) and IP-10 (r=0,32) levels were significantly (p<0.05) associated with a decrease of DAS28. Conclusions: ABA therapy leads to a significant reduction in serum levels of IL-6, IP-10, MMP3 and RF. The serum levels of IL-6 and IP-10 correlate with decrease activity of RA. (Table) . This trend was also observed for radiographic progression (mTSS change from BL),
